The chronic pain market is expected to witness steady growth, driven by the rising prevalence of chronic diseases, musculoskeletal disorders, neuropathic pain, arthritis, and age-related conditions. Additionally, the expected launch of emerging therapies such as SL1002 (Saol Therapeutics), Zenagamtide (Novo Nordisk), AbobotulinumtoxinA (DYSPORT; Ipsen), AncobotulinumtoxinA (XEOMIN; Merz Therapeutics), Retatrutide (LY3437943; Eli Lilly and Company), Suzetrigine (JOURNAVX; Vertex Pharmaceuticals), Esreboxetine (AXS-14; Axsome Therapeutics), and others will further accelerate the market growth. LAS VEGAS, Sept.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.